South Korea
OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company presented its latest study data from preclinical studies identifying synergistic effects in weight loss when using its non-alcoholic steatohepatitis (NASH) treatment candidate OLX702A in combination with semaglutide. The data was presented at TIDES USA 2023, an international conference dedicated to oligonucleotide and peptide therapeutics, held in San Diego, California, on May 7-10.
PharmAbcine to participate in BIO International Convention 2023
DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023.
Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia
SEOUL, South Korea--(BUSINESS WIRE)-- Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases. Phase 1 was conducted in Australia.
OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital·BioHealth Business Forum
SUWON, South Korea--(BUSINESS WIRE)-- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company signed a memorandum of understanding (MOU) with DynamiCure Biotechnology for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum recently held in Boston, Massachusetts.
Kalos Medical Announces Grant Award, Completion of Patient Recruitment of Clinical Trial
alos Medical, Inc. (“Kalos”), a developer of innovative and minimally invasive medical devices using proprietary catheter-based technology, announced that on April 24th it was selected as a participant in the 2023 Industrial Technology Innovation Project, administered by South Korea’s Ministry of Trade, Industry, and Energy
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
Hyundai Bioscience (KOSDAQ 048410) announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty' (code name: CP-COV03).
